• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Financial Officer Griffith Donald J. was granted 10,000 shares, increasing direct ownership by 2,667% to 10,375 units (SEC Form 4)

    7/15/25 7:35:20 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SONN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Griffith Donald J.

    (Last) (First) (Middle)
    100 OVERLOOK CENTER, SUITE 102

    (Street)
    PRINCETON, NJ 08540

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Sonnet BioTherapeutics Holdings, Inc. [ SONN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    07/11/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 07/11/2025 A 10,000 A (1) 10,375(2)(3) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. On July 11, 2025, the Reporting Person was granted 10,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on the earlier of (i) January 8, 2026, or (ii) the date of a "Change in Control" (as defined under the Issuer's 2020 Omnibus Equity Incentive Plan).
    2. Includes unvested restricted stock units.
    3. All amounts reflect the Issuer's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
    /s/ Donald J. Griffith 07/15/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SONN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SONN

    DatePrice TargetRatingAnalyst
    2/9/2022$5.00 → $2.00Buy
    BTIG
    12/20/2021$8.00 → $2.50Buy
    Chardan Capital
    12/16/2021$2.00Buy
    HC Wainwright & Co.
    9/15/2021$5.00Buy
    BTIG
    More analyst ratings

    $SONN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG reiterated coverage on Sonnet BioTherapeutics with a new price target

    BTIG reiterated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.00 from $5.00 previously

    2/9/22 6:54:44 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital reiterated coverage on Sonnet BioTherapeutics with a new price target

    Chardan Capital reiterated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.50 from $8.00 previously

    12/20/21 8:31:50 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Sonnet BioTherapeutics with a new price target

    HC Wainwright & Co. initiated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.00

    12/16/21 8:15:32 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SONN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sonnet Releases Virtual Investor "What This Means" Segment

    - Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221) - Watch the "What This Means" video here PRINCETON, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced the release of a Virtual Investor "What This Means" segment.As part of the segment, Dr. Richard Kenney, Chief Medical Officer, discussed its recent update on its SB221 clinical trial including that a) enrollment of

    8/11/25 9:15:00 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

    Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221) Topline safety, cytokine, and efficacy data suggest a strong potential for clinical benefit using the current maximum dose of SON-1010 A second patient with PROC in the E6 combination cohort recently had a confirmed PR, so 2 out of 3 total patients had a tumor response at that dose After completing enrollment of the expansion group at that top dose, a new E7 cohort has been added to examine the safety and effectiveness of a 25% higher maintenance dose of SON-1010 PRINCETON, N.J., Aug. 04, 2025 (GLOBE NEW

    8/4/25 8:40:00 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

    PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics, Inc., (NASDAQ:SONN) ("Sonnet" or the "Company") today announced that it has entered into a definitive agreement (the "Business Combination Agreement", or the "BCA") for a business combination (the "Business Combination") with Rorschach I LLC ("Rorschach"), a newly-formed entity formed by an entity affiliated with Atlas Merchant Capital LLC ("Atlas"), an affiliate of Paradigm Operations LP ("Paradigm"), and additional sponsors (all together, the "Sponsors"), to transform its business by building a reserve of HYPE, the token of the Hyperliquid Layer-1 blockchain. At the closing of the Business Combination, the newly-

    7/14/25 6:00:00 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SONN
    SEC Filings

    View All

    SEC Form DEF 14A filed by Sonnet BioTherapeutics Holdings Inc.

    DEF 14A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)

    8/26/25 5:01:29 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Sonnet BioTherapeutics Holdings Inc.

    10-Q - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)

    8/13/25 4:06:40 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sonnet BioTherapeutics Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)

    8/1/25 4:58:26 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SONN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Mohan Pankaj bought 34,375 shares, increasing direct ownership by 137% to 59,526 units (SEC Form 4)

    4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

    10/27/23 8:00:08 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rao Raghu bought 15,625 shares, increasing direct ownership by 1,315% to 16,813 units (SEC Form 4)

    4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

    10/27/23 8:00:10 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SONN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Medical Officer Kenney Richard T

    4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

    8/21/25 4:48:43 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Kenney Richard T was granted 8,000 shares, increasing direct ownership by 582% to 9,374 units (SEC Form 4)

    4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

    7/15/25 7:35:19 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bhatt Nailesh was granted 10,000 shares, increasing direct ownership by 1,828% to 10,547 units (SEC Form 4)

    4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

    7/15/25 7:35:19 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SONN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Sonnet BioTherapeutics Holdings Inc. (Amendment)

    SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)

    1/2/24 4:19:28 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Sonnet BioTherapeutics Holdings Inc. (Amendment)

    SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)

    11/17/23 11:32:52 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Sonnet BioTherapeutics Holdings Inc. (Amendment)

    SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)

    11/6/23 11:35:23 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SONN
    Leadership Updates

    Live Leadership Updates

    View All

    Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

    PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced with deep and profound sadness the tragic passing of Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer. The Company's Board of Directors has unanimously approved the appointment of current board member Raghu Rao, as Interim Chief Executive Officer of the Company, and the promotion of Stephen McAndrew, Ph.D., the Company's current Chief Business Officer, to President and Chief Business Officer of the Company. The Board intends

    4/1/25 7:30:00 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

    PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the appointment of Stephen J. McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025. Dr. McAndrew brings more than 30 years of experience with various business models and types of transactional agreements involving biologics at different stages of development. During the course of his tenure at Sonnet, Dr. McAndrew has served as Vice President and then Senior Vice President, Business Development, and has been responsible for developing and leading the Compa

    2/13/25 8:30:00 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company's Business Advisory Committee

    Ms. McNeill is a former executive of Pfizer and an entrepreneur with expertise in marketing and public relations; she will sit on the Board of Directors and serve as the Chairperson of Sonnet's newly formed Business Advisory Committee (BAC)The BAC will advise the company on business collaborations, communications and interactions with the Federal GovernmentPRINCETON, NJ / ACCESSWIRE / September 26, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that Lori McNeill has been appointed to the Company's Board of Directors. Ms. McNeill's Board position will also round out the composition of the compan

    9/26/22 8:00:00 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care